Awakening guardian angels: drugging the p53 pathway

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · see citing works

<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · see citing works

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · see citing works

p53, guardian of the genome

Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138 · see citing works

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · see citing works

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338 · see citing works

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407 · see citing works

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113 · see citing works

hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase

Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,653 · see citing works

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · see citing works

p53 in health and disease

Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,275 · see citing works

Negative Control of p53 by Sir2α Promotes Cell Survival under Stress

Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081 · see citing works

A Hot Spot of Binding Energy in a Hormone-Receptor Interface

Clackson, T., & Wells, J. A. (1995) · Science · doi:10.1126/science.7529940 · Cited by 1,987 · see citing works

The first 30 years of p53: growing ever more complex.

Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967 · see citing works

Amplification of a gene encoding a p53-associated protein in human sarcomas

Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949 · see citing works

Restoration of p53 function leads to tumour regression in vivo

Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · see citing works

The PARP superfamily

Amé, J., Spenlehauer, C., & de MURCIA, G. (2004) · BioEssays · doi:10.1002/bies.20085 · Cited by 1,463 · see citing works

Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53

de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420 · cited 1× · see citing works

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd839 · Cited by 1,391 · see citing works

p53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR Signaling

Budanov, A. V., & Karin, M. (2008) · Cell · doi:10.1016/j.cell.2008.06.028 · Cited by 1,326 · cited 1× · see citing works

Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53

Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280 · cited 1× · see citing works

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3

Baselga, J. M., & Swain, S. M. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2656 · Cited by 1,144 · see citing works

Modulation of microRNA processing by p53

Suzuki, H. I., Yamagata, K., Sugimoto, K., Iwamoto, T., Kato, S., & Miyazono, K. (2009) · Nature · doi:10.1038/nature08199 · Cited by 1,125 · see citing works

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · see citing works

Mdm2 Is a RING Finger-dependent Ubiquitin Protein Ligase for Itself and p53

Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H., & Weissman, A. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8945 · Cited by 1,044 · see citing works

Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region

Kudo, N. R., Matsumori, N., Taoka, H., Fujiwara, D., Schreiner, E. P., Wolff, B., Yoshida, M., & Horinouchi, S. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.9112 · Cited by 1,033 · see citing works

Resistance to therapy caused by intragenic deletion in BRCA2

Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011 · see citing works

The MDM2 gene amplification database

Momand, J. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3453 · Cited by 982 · see citing works

p53 and Human Cancer: The First Ten Thousand Mutations

Hainaut, P. L., & Hollstein, M. C. (1999) · Advances in cancer research · doi:10.1016/s0065-230x(08)60785-x · Cited by 980 · see citing works

Regulation of the specific DNA binding function of p53

Hupp, T. R., Meek, D. W., Midgley, C., & Lane, D. P. (1992) · Cell · doi:10.1016/0092-8674(92)90562-q · Cited by 910 · see citing works

Human SIR2 deacetylates p53 and antagonizes PML/p53‐induced cellular senescence

Langley, E., Pearson, M., Faretta, M., Bauer, U., Frye, R. A., Minucci, S., Pelicci, P. G., & Kouzarides, T. (2002) · The EMBO Journal · doi:10.1093/emboj/21.10.2383 · Cited by 859 · see citing works

Modelling Myc inhibition as a cancer therapy

Soucek, L., Whitfield, J. R., Martins, C. P., Finch, A. J., Murphy, D. J., Sodir, N. M., Karnezis, A. N., Swigart, L. B., Nasi, S., & Evan, G. I. (2008) · Nature · doi:10.1038/nature07260 · Cited by 822 · see citing works

Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses

Rubbi, C. P., & Milner, J. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg579 · Cited by 811 · see citing works

Pharmacological Rescue of Mutant p53 Conformation and Function

Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 802 · see citing works

Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors

Issaeva, N., Bozko, P. M., Enge, M., Protopopova, M., Verhoef, L. G. G. C., Masucci, M. G., Pramanik, A., & Selivanova, G. (2004) · Nature Medicine · doi:10.1038/nm1146 · Cited by 749 · see citing works

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708 · see citing works

Structure-Based Design of Spiro-oxindoles as Potent, Specific Small-Molecule Inhibitors of the MDM2−p53 Interaction

Ding, K., Lu, Y., Nikolovska-Coleska, Z., Wang, G., Qiu, S., Shangary, S., Gao, W., Qin, D., Stuckey, J., Krajewski, K., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051122a · Cited by 702 · see citing works

Structural Biology of the Tumor Suppressor p53

Joerger, A. C., & Fersht, A. R. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.060806.091238 · Cited by 699 · see citing works

Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.

Sigal, A., & Rotter, V. (2000) · PubMed · Cited by 669 · see citing works

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660 · see citing works

Structure-based design of potent non-peptide MDM2 inhibitors

Ding, K., Lu, Y., Nikolovska-Coleska, Z., Qiu, S., Ding, Y., Gao, W., Stuckey, J., Krajewski, K., Roller, P. P., Tomita, Y., et al. (2005) · Journal of the American Chemical Society · doi:10.1021/ja051147z · Cited by 657 · see citing works

The ARF/p53 pathway.

Sherr, C. J., & Weber, J. D. (2000) · Current Opinion in Genetics &amp; Development · doi:10.1016/s0959-437x(99)00038-6 · Cited by 654 · see citing works

The Regulation of AMPK β1, TSC2, and PTEN Expression by p53: Stress, Cell and Tissue Specificity, and the Role of These Gene Products in Modulating the IGF-1-AKT-mTOR Pathways

Feng, Z., Hu, W., de Stanchina, E., Teresky, A. K., Jin, S., Lowe, S., & Levine, A. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4149 · Cited by 633 · see citing works

Regulation of HDM2 activity by the ribosomal protein L11

Lohrum, M. A. E., Ludwig, R. L., Kubbutat, M. H. G., Hanlon, M., & Vousden, K. H. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00134-x · Cited by 626 · see citing works

Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy

Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623 · see citing works

Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation

Milner, J., & Medcalf, E. (1991) · Cell · doi:10.1016/0092-8674(91)90384-b · Cited by 612 · see citing works

Modeling the Therapeutic Efficacy of p53 Restoration in Tumors

Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600 · cited 1× · see citing works

Inactivation of the p53 pathway in retinoblastoma

Laurie, N. A., Donovan, S. L., Shih, C.-S., Zhang, J., Mills, N., Fuller, C., Teunisse, A., Lam, S., Ramos, Y., Mohan, A., et al. (2006) · Nature · doi:10.1038/nature05194 · Cited by 595 · see citing works

PRIMA-1 reactivates mutant p53 by covalent binding to the core domain

Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592 · see citing works

Reactivation of the p53 Tumor Suppressor Pathway by a Stapled p53 Peptide

Bernal, F., Tyler, A. F., Korsmeyer, S. J., Walensky, L. D., & Verdine, G. L. (2007) · Journal of the American Chemical Society · doi:10.1021/ja0693587 · Cited by 559 · see citing works

p53: traffic cop at the crossroads of DNA repair and recombination

Sengupta, S., & Harris, C. C. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1546 · Cited by 544 · see citing works

MDM2 inhibitors for cancer therapy

Vassilev, L. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.002 · Cited by 532 · see citing works

A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage.Preprint

Linke, S. P., Clarkin, K., Leonardo, A. D., Tsou, A.-P., & Wahl, G. M. (1996) · Genes & Development · doi:10.1101/gad.10.8.934 · Cited by 531 · see citing works

Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 Activator

Laı́n, S., Hollick, J. J., Campbell, J., Staples, O. D., Higgins, M., Aoubala, M., McCarthy, A. R., Appleyard, V. C. L., Murray, K. E., Baker, L., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.03.004 · Cited by 523 · see citing works

Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53

Parant, J., Chavez-Reyes, A., Little, N. A., Yan, W., Reinke, V., Jochemsen, A. G., & Lozano, G. (2001) · Nature Genetics · doi:10.1038/ng714 · Cited by 517 · see citing works

Base Excision Repair Is Impaired in Mammalian Cells Lacking Poly(ADP-ribose) Polymerase-1

Dantzer, F., de la Rubia, G., Murcia, J. M., Hostomský, Z., de MURCIA, G., & Schreiber, V. (2000) · Biochemistry · doi:10.1021/bi0003442 · Cited by 505 · see citing works

Transcription-independent pro-apoptotic functions of p53

Moll, U. M., Wolff, S., Speidel, D., & Deppert, W. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.09.007 · Cited by 468 · see citing works

Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy

Bullock, A. N., Henckel, J., & Fersht, A. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203434 · Cited by 435 · see citing works

Small peptides activate the latent sequence-specific DNA binding function of p53

Hupp, T. R., Sparks, A., & Lane, D. P. (1995) · Cell · doi:10.1016/0092-8674(95)90165-5 · Cited by 433 · see citing works

Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in Cells

Grasberger, B. L., Lu, T., Schubert, C., Parks, D. J., Carver, T. E., Koblish, H. K., Cummings, M. D., LaFrance, L. V., Milkiewicz, K. L., Calvo, R. R., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049137g · Cited by 433 · see citing works

Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX

Pazgier, M., Liu, M., Zou, G., Yuan, W., Li, C., Li, C., Li, J., Monbo, J., Zella, D., Tarasov, S. G., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900947106 · Cited by 391 · see citing works

Targeted rescue of a destabilized mutant of p53 by an in silico screened drug

Boeckler, F. M., Joerger, A. C., Jaggi, G., Rutherford, T. J., Veprintsev, D. B., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805326105 · Cited by 389 · see citing works

Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase

Honda, R., & Yasuda, H. (2000) · Oncogene · doi:10.1038/sj.onc.1203464 · Cited by 376 · see citing works

HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53

Linares, L. K., Hengstermann, A., Ciechanover, A., Müller, S., & Scheffner, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2030930100 · Cited by 361 · see citing works

The inherent instability of mutant p53 is alleviated by Mdm2 or p16 INK4a lossPreprint

Terzian, T., Suh, Y., Iwakuma, T., Post, S. M., Neumann, M., Lang, G. A., Pelt, C. S. V., & Lozano, G. (2008) · Genes & Development · doi:10.1101/gad.1662908 · Cited by 356 · see citing works

Structural basis for understanding oncogenic p53 mutations and designing rescue drugs

Joerger, A. C., Ang, H. C., & Fersht, A. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607286103 · Cited by 354 · see citing works

The Human ARF Cell Cycle Regulatory Gene Promoter Is a CpG Island Which Can Be Silenced by DNA Methylation and Down-Regulated by Wild-Type p53

Robertson, K. D., & Jones, P. A. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.11.6457 · Cited by 352 · see citing works

Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain

Selivanova, G., Iotsova, V., Okan, İ., Fritsche, M., Ström, M., Groner, B., Grafström, R. C., & Wiman, K. G. (1997) · Nature Medicine · doi:10.1038/nm0697-632 · Cited by 343 · see citing works

MDM2 interacts with MDMX through their RING finger domains

Tanimura, S., Ohtsuka, S., Mitsui, K., Shirouzu, K., Yoshimura, A., & Ohtsubo, M. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00254-9 · Cited by 324 · see citing works

Discovering novel ligands for macromolecules using X-ray crystallographic screening

Nienaber, V. L., Richardson, P. L., Klighofer, V., Bouska, J. J., Giranda, V. L., & Greer, J. (2000) · Nature Biotechnology · doi:10.1038/80319 · Cited by 322 · see citing works

Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells

Yang, Y., Ludwig, R. L., Jensen, J. P., Pierre, S. A., Medaglia, M. V., Davydov, I. V., Safiran, Y. J., Oberoi, P., Kenten, J. H., Phillips, A. C., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.029 · Cited by 321 · see citing works

Amplification of <i>Mdmx</i> (or <i>Mdm4</i> ) Directly Contributes to Tumor Formation by Inhibiting p53 Tumor Suppressor Activity

Danovi, D., Meulmeester, E., Pasini, D., Migliorini, D., Capra, M., Frenk, R., de Graaf, P., Francoz, S., Gasparini, P., Gobbi, A., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.13.5835-5843.2004 · Cited by 310 · see citing works

Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group.

Green, D. M., Breslow, N. E., Beckwith, J. B., Finklestein, J. Z., Grundy, P. E., Thomas, P. R. M., Kim, T., Shochat, S. J., Haase, G. M., Ritchey, M. L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.237 · Cited by 305 · see citing works

A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53

Sur, S., Pagliarini, R. A., Bunz, F., Rago, C., Diaz, L. A., Kinzler, K. W., Vogelstein, B., & Papadopoulos, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813333106 · Cited by 293 · see citing works

Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans

Linke, K., Mace, P. D., Smith, C. A., Vaux, D. L., Silke, J., & Day, C. L. (2008) · Cell Death &amp; Differentiation · doi:10.1038/sj.cdd.4402309 · Cited by 288 · see citing works

Inhibition of RNA polymerase II as a trigger for the p53 response

Ljungman, M. E., Zhang, F., Chen, F., Rainbow, A. J., & McKay, B. C. (1999) · Oncogene · doi:10.1038/sj.onc.1202356 · Cited by 287 · see citing works

Stabilization of the MDM2 Oncoprotein by Interaction with the Structurally Related MDMX Protein

Sharp, D. A., Kratowicz, S. A., Sank, M. J., & George, D. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.53.38189 · Cited by 286 · see citing works

Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis

Maclean, K. H., Dorsey, F. C., Cleveland, J. L., & Kastan, M. B. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33700 · Cited by 273 · see citing works

Mutant p53: an oncogenic transcription factor

Strano, S., Dell’Orso, S., Agostino, S. D., Fontemaggi, G., Sacchi, A., & Blandino, G. (2007) · Oncogene · doi:10.1038/sj.onc.1210296 · Cited by 270 · see citing works

Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-κB-dependent mechanism of p53 suppression in tumors

Gurova, K. V., Hill, J. E., Guo, C., Prokvolit, A., Burdelya, L. G., Samoylova, E. M., Khodyakova, A. V., Ganapathi, R. N., Ganapathi, M. K., Tararova, N. D., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508888102 · Cited by 266 · see citing works

Mutual Dependence of MDM2 and MDMX in Their Functional Inactivation of p53

Gu, J., Kawai, H., Nie, L., Kitao, H., Wiederschain, D., Jochemsen, A. G., Parant, J. M., Lozano, G., & Yuan, Z.-M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200150200 · Cited by 265 · see citing works

Phase I trial of elactocin

Newlands, E. S., Rustin, G. J. S., & Brampton, M. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.415 · Cited by 253 · see citing works

Dissecting cellular processes using small molecules: identification of colchicine-like, taxol-like and other small molecules that perturb mitosis

Haggarty, S. J., Mayer, T. U., Miyamoto, D. T., Fathi, R., King, R. W., Mitchison, T. J., & Schreiber, S. L. (2000) · Chemistry &amp; Biology · doi:10.1016/s1074-5521(00)00101-0 · Cited by 251 · see citing works

p53 Protein Exhibits 3′-to-5′ Exonuclease Activity

Mummenbrauer, T., Janus, F., Müller, B., Wiesmüller, L., Deppert, W., & Große, F. (1996) · Cell · doi:10.1016/s0092-8674(00)81309-4 · Cited by 249 · see citing works

Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification.

Riemenschneider, M. J., Büschges, R., Wolter, M., REIFENBERGER, J., Boström, J. P., Kraus, J. A., Schlegel, U. S., & Reifenberger, G. (1999) · PubMed · Cited by 247 · see citing works

MDM2 promotes ubiquitination and degradation of MDMX

Pan, Y., & Chen, J. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.15.5113-5121.2003 · Cited by 246 · cited 1× · see citing works

Tumor Suppressor p53: Analysis of Wild-Type and Mutant p53 Complexes

Milner, J., Medcalf, E., & Cook, A. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.1.12 · Cited by 243 · see citing works

Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms

Stad, R., Little, N. A., Xirodimas, D. P., Frenk, R., van der Eb, A. J., Lane, D. P., Saville, M. K., & Jochemsen, A. G. (2001) · The EMBO Reports · doi:10.1093/embo-reports/kve227 · Cited by 234 · see citing works

Mutant conformation of p53

Stephen, C. W., & Lane, D. P. (1992) · Journal of Molecular Biology · doi:10.1016/0022-2836(92)90386-x · Cited by 211 · see citing works

Tumor suppression and normal aging in mice with constitutively high p53 activity

Mendrysa, S. M., O'Leary, K. A., McElwee, M. K., Michalowski, J., Eisenman, R. N., Powell, D. A., & Perry, M. E. (2006) · Genes &amp; Development · doi:10.1101/gad.1378506 · Cited by 210 · see citing works

What the papers say: The p53‐mdm2 autoregulatory feedback loop: A paradigm for the regulation of growth control by p53?

Picksley, S. M., & Lane, D. P. (1993) · BioEssays · doi:10.1002/bies.950151008 · Cited by 207 · see citing works

Activation of p53 by MDM2 Antagonists Can Protect Proliferating Cells from Mitotic Inhibitors

Carvajal, D. M., Tovar, C., Yang, H. S., Vu, B. T., Heimbrook, D. C., & Vassilev, L. T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3576 · Cited by 202 · see citing works

Suppression of the Deubiquitinating Enzyme USP5 Causes the Accumulation of Unanchored Polyubiquitin and the Activation of p53

Dayal, S., Sparks, A., Jacob, J., Allende-Vega, N., Lane, D. P., & Saville, M. K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805871200 · Cited by 200 · see citing works

Treatment of Terminal Peritoneal Carcinomatosis by a Transducible p53-Activating Peptide

Snyder, E. L., Meade, B. R., Saenz, C. C., & Dowdy, S. F. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020036 · Cited by 199 · see citing works

Identification of Nuclear Export Inhibitors with Potent Anticancer Activity In vivo

Mutka, S. C., Yang, W. Q., Dong, S. D., Ward, S. L., Craig, D. A., Timmermans, P. B. M. W. M., & Murli, S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-0858 · Cited by 195 · see citing works

Comparative study of the p53-mdm2 and p53-MDMX interfaces

Böttger, V., Böttger, A., Garcia-Echeverria, C., Ramos, Y. F., van der Eb, A. J., Jochemsen, A. G., & Lane, D. P. (1999) · Oncogene · doi:10.1038/sj.onc.1202281 · Cited by 189 · see citing works

An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors

Brummelkamp, T. R., Fabius, A. W. M., Mullenders, J., Madiredjo, M., Velds, A., Kerkhoven, R. M., Bernards, R., & Beijersbergen, R. L. (2006) · Nature Chemical Biology · doi:10.1038/nchembio774 · Cited by 187 · see citing works

Characterization of the p53-rescue drug CP-31398 in vitro and in living cells

Rippin, T. M., Bykov, V. J. N., Freund, S. M. V., Selivanova, G., Wiman, K. G., & Fersht, A. R. (2002) · Oncogene · doi:10.1038/sj.onc.1205362 · Cited by 186 · see citing works

The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest

Foster, S. A., Demers, G. W., Etscheid, B. G., & Galloway, D. A. (1994) · Journal of Virology · doi:10.1128/jvi.68.9.5698-5705.1994 · Cited by 185 · see citing works

From the Cover: p53 accumulates but is functionally impaired when DNA synthesis is blocked

Gottifredi, V., Shieh, S.-Y., Taya, Y., & Prives, C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.021282898 · Cited by 181 · see citing works

No PUMA, no death

Yu, J., & Zhang, L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00249-6 · Cited by 180 · see citing works

A Single Nucleotide Polymorphism in the MDM2 Gene: From a Molecular and Cellular Explanation to Clinical Effect

Bond, G. L., Hu, W., & Levine, A. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0825 · Cited by 176 · see citing works

Control of p53 ubiquitination and nuclear export by MDM2 and ARF.

Zhang, Y., & Xiong, Y. (2001) · PubMed · Cited by 176 · see citing works

Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?

Li, Y., & Prives, C. L. (2007) · Oncogene · doi:10.1038/sj.onc.1210311 · Cited by 174 · see citing works

MDM2-Dependent Downregulation of p21 and hnRNP K Provides a Switch between Apoptosis and Growth Arrest Induced by Pharmacologically Activated p53

Enge, M., Bao, W., Hedström, E., Jackson, S. P., Moumen, A., & Selivanova, G. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.019 · Cited by 171 · see citing works

Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Wade, M., & Wahl, G. M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0423 · Cited by 170 · see citing works

Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo

Koblish, H. K., Zhao, S., Franks, C. F., Donatelli, R. R., Tominovich, R. M., LaFrance, L. V., Leonard, K. A., Gushue, J. M., Parks, D. J., Calvo, R. R., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0199 · Cited by 164 · see citing works

DNA damage-induced MDMX degradation is mediated by MDM2

Kawai, H., Wiederschain, D., Kitao, H., Stuart, J., Tsai, K. K. C., & Yuan, Z.-M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308295200 · Cited by 163 · cited 1× · see citing works

Cancer-Associated Mutations in the MDM2 Zinc Finger Domain Disrupt Ribosomal Protein Interaction and Attenuate MDM2-Induced p53 Degradation

Lindström, M. S., Jin, A., Deisenroth, C., Wolf, G. W., & Zhang, Y. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01307-06 · Cited by 149 · see citing works

Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53.

Ramos, Y. F., Stad, R. K., Attema, J., Peltenburg, L. T. C., van der Eb, A. J., & Jochemsen, A. G. (2001) · PubMed · Cited by 149 · see citing works

p53 accumulates but is functionally impaired when DNA synthesis is blocked

Gottifredi, V., Shieh, S.-Y., Taya, Y., & Prives, C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.3.1036 · Cited by 147 · see citing works

Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2

de Graaf, P., Little, N. A., Ramos, Y. F. M., Meulmeester, E., Letteboer, S. J. F., & Jochemsen, A. G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213034200 · Cited by 143 · cited 1× · see citing works

Specific activation of the p53 pathway by low dose actinomycin D: A new route to p53 based cyclotherapy

Choong, M. L., Yang, H. C., Lee, M. A., & Lane, D. P. (2009) · Cell Cycle · doi:10.4161/cc.8.17.9503 · Cited by 141 · see citing works

Reactivation of Mutant p53 through Interaction of a C-Terminal Peptide with the Core Domain

Selivanova, G., Ryabchenko, L. G., Jansson, E. Å., Iotsova, V., & Wiman, K. G. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3395 · Cited by 139 · see citing works

p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2.

Esteller, M., Cordon‐Cardo, C., Corn, P. G., Meltzer, S. J., Pohar, K. S., Watkins, D. N., Capellá, G., Peinado, M. A., Matías‐Guiu, X., Prat, J., et al. (2001) · PubMed · Cited by 132 · see citing works

Mycophenolic Acid Activation of p53 Requires Ribosomal Proteins L5 and L11

Sun, X., Dai, M., & Lu, H. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801387200 · Cited by 120 · see citing works

Ablation of Key Oncogenic Pathways by RITA-Reactivated p53 Is Required for Efficient Apoptosis

Grinkevich, V. V., Nikulenkov, F., Shi, Y., Enge, M., Bao, W., Malyukova, A., Gluch, A., Kel, A. E., Sangfelt, O., & Selivanova, G. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.021 · Cited by 118 · see citing works

Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect.

Nishizaki, M., Fujiwara, T., Tanida, T., HIZUTA, A., Nishimori, H., Tokino, T., Nakamura, Y., Bouvet, M., Roth, J., & Tanaka, N. (1999) · PubMed · Cited by 118 · see citing works

Conformational and Molecular Basis for Induction of Apoptosis by a p53 C-terminal Peptide in Human Cancer Cells

Kim, A. L., Raffo, A. J., Brandt‐Rauf, P. W., Pincus, M. R., Monaco, R. R., Abarzúa, P., & Fine, R. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.49.34924 · Cited by 114 · see citing works

Cancer Specific Viruses and the Development of ONYX-015

McCormick, F. P. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.216 · Cited by 106 · see citing works

The Spectrum of Mutations at the p53 Locus

Levine, A. J., Wu, M. C., Chang, A., Silver, A., Attiyeh, E. F., Lin, J., & Epstein, C. B. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb12115.x · Cited by 105 · see citing works

Transcriptional activities of mutant p53: When mutations are more than a loss

Kim, E. L., & Deppert, W. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20271 · Cited by 102 · see citing works

p53 functions in the incorporation step in DNA base excision repair in mouse liver mitochondria

de Souza-Pinto, N. C., Harris, C. C., & Bohr, V. A. (2004) · Oncogene · doi:10.1038/sj.onc.1207874 · Cited by 101 · see citing works

High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx

Czarna, A., Popowicz, G. M., Pęcak, A., Wolf, S., Dubin, G., & Holak, T. A. (2009) · Cell Cycle · doi:10.4161/cc.8.8.8185 · Cited by 99 · see citing works

NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro

Krajewski, M., Ozdowy, P., D’Silva, L., Rothweiler, U., & Holak, T. A. (2005) · Nature Medicine · doi:10.1038/nm1105-1135 · Cited by 96 · see citing works

Significance of HDMX‐S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis

Bartel, F., Schulz, J., Böhnke, A., Blümke, K., Kappler, M., Bache, M., Schmidt, H., Würl, P., Taubert, H. W., & Hauptmann, S. (2005) · International Journal of Cancer · doi:10.1002/ijc.21206 · Cited by 93 · see citing works

Flexibility: the key to p53 function?

Milner, J. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)88954-9 · Cited by 88 · see citing works

Small-Molecule Activation of p53 Blocks Hypoxia-Inducible Factor 1α and Vascular Endothelial Growth Factor Expression In Vivo and Leads to Tumor Cell Apoptosis in Normoxia and Hypoxia

Yang, J., Ahmed, A., Poon, E., Perusinghe, N. P., Brandon, A. D. H., Box, G., Valenti, M. R., Eccles, S. A., Rouschop, K. M. A., Wouters, B. G., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00959-08 · Cited by 85 · see citing works

Increased Radioresistance and Accelerated B Cell Lymphomas in Mice with Mdmx Mutations that Prevent Modifications by DNA-Damage-Activated Kinases

Wang, Y. V., Leblanc, M., Wade, M., Jochemsen, A. G., & Wahl, G. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.05.008 · Cited by 79 · see citing works

A new anti-p53 monoclonal antibody, previously reported to be directed against the large T antigen of simian virus 40.

Milner, J., Cook, A., & Sheldon, M. J. (1987) · PubMed · Cited by 78 · see citing works

Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein–protein interaction through structure-based drug design

Parks, D. J., LaFrance, L. V., Calvo, R. R., Milkiewicz, K. L., Marugán, J., Raboisson, P., Schubert, C., Koblish, H. K., Zhao, S., Franks, C. F., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.03.055 · Cited by 76 · see citing works

DNA Protein Cross-Links Produced by NSC 652287, a Novel Thiophene Derivative Active Against Human Renal Cancer Cells

Nieves‐Neira, W., Rivera, M. I., Kohlhagen, G., Hursey, M. L., Pourquier, P., Sausville, E. A., & Pommier, Y. G. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.3.478 · Cited by 70 · see citing works

Cyclin-Dependent Kinase Inhibitors Sensitize Tumor Cells to Nutlin-Induced Apoptosis: a Potent Drug Combination

Cheok, C. F., Dey, A., & Lane, D. P. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0161 · Cited by 69 · see citing works

Structure-based design of molecular cancer therapeutics

van Montfort, R. L. M., & Workman, P. (2009) · Trends in biotechnology · doi:10.1016/j.tibtech.2009.02.003 · Cited by 67 · see citing works

Family Feud in Chemosensitvity: p73 and Mutant p53

Irwin, M. S. (2004) · Cell Cycle · doi:10.4161/cc.3.3.768 · Cited by 63 · see citing works

Novel 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity

Leonard, K. A., Marugán, J., Raboisson, P., Calvo, R. R., Gushue, J. M., Koblish, H. K., Lattanze, J., Zhao, S., Cummings, M. D., Player, M. R., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.04.009 · Cited by 61 · see citing works

RNA synthesis block by 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) triggers p53-dependent apoptosis in human colon carcinoma cells

Poele, R. T., Okorokov, A. L., & Joel, S. P. (1999) · Oncogene · doi:10.1038/sj.onc.1202961 · Cited by 60 · see citing works

Selective toxicity of the tricyclic thiophene NSC 652287 in renal carcinoma cell lines

Rivera, M. I., Stinson, S. F., Vistica, D. T., Jorden, J. L., Kenney, S., & Sausville, E. A. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00046-5 · Cited by 55 · see citing works

p53 Modulates RPA-Dependent and RPA-Independent WRN Helicase Activity

Sommers, J. A., Sharma, S., Doherty, K. M., Karmakar, P., Yang, Q., Kenny, M. K., Harris, C. C., & Brosh, R. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-03-0231 · Cited by 54 · see citing works

Pilot screening programme for small molecule activators of p53

Berkson, R., Hollick, J. J., Westwood, N. J., Woods, J. A., Lane, D. P., & Laı́n, S. (2005) · International Journal of Cancer · doi:10.1002/ijc.20968 · Cited by 52 · see citing works

High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter

Sohn, T. A., Bansal, R. K., Su, G. H., Murphy, K. M., & Kern, S. E. (2002) · Carcinogenesis · doi:10.1093/carcin/23.6.949 · Cited by 49 · see citing works

Tumor Suppressing Gene Therapy

Fang, B., & Roth, J. A. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.210 · Cited by 47 · see citing works

Dissection of the sequence-specific DNA binding and exonuclease activities reveals a superactive yet apoptotically impaired mutant p53 protein

Ahn, J., Poyurovsky, M. V., Baptiste, N., Beckerman, R., Cain, C. R., Mattia, M., McKinney, K. M., Zhou, J., Zupnick, A., Gottifredi, V., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.10.8548 · Cited by 29 · see citing works

Curing Cancer with p53

Lane, D. P. (2004) · New England Journal of Medicine · doi:10.1056/nejmcibr041288 · Cited by 21 · see citing works

Characterization, chemical optimization and anti-tumor activity of a tubulin poison identified by a p53-based phenotypic screen

Staples, O. D., Hollick, J. J., Campbell, J., Higgins, M., McCarthy, A. R., Appleyard, V. C. L., Murray, K. E., Baker, L., Thompson, A. M., Ronseaux, S., et al. (2008) · Cell Cycle · doi:10.4161/cc.7.21.6982 · Cited by 15 · see citing works

Activation of a unique p53-dependent DNA damage response

Yang, J., Ahmed, A., & Ashcroft, M. A. (2009) · Cell Cycle · doi:10.4161/cc.8.10.8326 · Cited by 15 · see citing works

Activation of p53 by scaffold-stabilised expression of Mdm2-binding peptides: visualisation of reporter gene induction at the single-cell level

Karlsson, G. B., Jensen, A., Stevenson, L. F., Woods, Y. L., Lane, D. P., & Sørensen, M. S. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602143 · Cited by 14 · see citing works

Basic Cell Cycle and Cancer Research: Is Harmony Possible?

Blagosklonny, M. V. (2002) · Cell Cycle · doi:10.4161/cc.1.1.92 · Cited by 5 · see citing works

Nobel Prize: Heroes for a Heroic Age

Johnson, R. T., & Downes, C. S. (2002) · Cell Cycle · doi:10.4161/cc.1.1.93 · Cited by 2 · see citing works

Systematic identification of genomic markers of drug sensitivity in cancer cells

Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · see citing works

Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies

Pistritto, G., Trisciuoglio, D., Ceci, C., Garufi, A., & D’Orazi, G. (2016) · Aging · doi:10.18632/aging.100934 · Cited by 1,670 · see citing works

MDM2, MDMX and p53 in oncogenesis and cancer therapy

Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279 · see citing works

Senescence in tumours: evidence from mice and humans

Collado, M., & Serrano, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2772 · Cited by 1,124 · see citing works

Senescence and aging: the critical roles of p53

Rufini, A., Tucci, P., Celardo, I., & Melino, G. (2013) · Oncogene · doi:10.1038/onc.2012.640 · Cited by 798 · see citing works

Drugging the p53 pathway: understanding the route to clinical efficacy

Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 723 · see citing works

Radiation-induced cell death mechanisms

Eriksson, D., & Stigbrand, T. I. (2010) · Tumor Biology · doi:10.1007/s13277-010-0042-8 · Cited by 666 · see citing works

The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches

Joerger, A. C., & Fersht, A. R. (2016) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014710 · Cited by 658 · see citing works

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595 · see citing works

On the binding affinity of macromolecular interactions: daring to ask why proteins interact

Kastritis, P. L., & Bonvin, A. M. J. J. (2012) · Journal of The Royal Society Interface · doi:10.1098/rsif.2012.0835 · Cited by 519 · see citing works

Oncogenes and Tumor Suppressor GenesPreprint

Lee, E. Y., & Muller, W. J. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003236 · Cited by 515 · see citing works

Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment

Zhao, Y., Aguilar, A., Bernard, D., & Wang, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501092z · Cited by 462 · see citing works

Advances in Targeting ‘Undruggable’ transcription Factors With Small Molecules

Henley, M. J., & Koehler, A. N. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00199-0 · Cited by 409 · see citing works

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406 · see citing works

The role of mutant p53 in human cancer

Goh, A. M., Coffill, C. R., & Lane, D. P. (2010) · The Journal of Pathology · doi:10.1002/path.2784 · Cited by 398 · see citing works

Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development

Vu, B., Wovkulich, P., Pizzolato, G., Lovey, A., Ding, Q., Jiang, N., Liu, J.-J., Zhao, C., Glenn, K., Wen, Y., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4000657 · Cited by 395 · see citing works

Translating p53 into the clinic

Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.174 · Cited by 381 · see citing works

The molecular pathogenesis of head and neck squamous cell carcinoma

Rothenberg, S. M., & Ellisen, L. W. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59889 · Cited by 362 · see citing works

Protein Folding and Mechanisms of Proteostasis

Díaz‐Villanueva, J. F., Díaz-Molina, R. J., & García‐González, V. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160817193 · Cited by 341 · see citing works

p53 Acetylation: Regulation and Consequences

Reed, S. M., & Quelle, D. E. (2014) · Cancers · doi:10.3390/cancers7010030 · Cited by 330 · see citing works

Tumor-Suppressor Functions of the TP53 PathwayPreprint

Aubrey, B. J., Strasser, A., & Kelly, G. L. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026062 · Cited by 331 · see citing works

MDM4 is a key therapeutic target in cutaneous melanoma

Gembarska, A., Luciani, F., Fedele, C., Russell, E. A., Dewaele, M., Villar, S., Zwolinska, A., Haupt, S., de Lange, J., Yip, D., et al. (2012) · Nature Medicine · doi:10.1038/nm.2863 · Cited by 327 · see citing works

Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma

Elmusrati, A., Wang, J. Q., & Wang, C. (2021) · International Journal of Oral Science · doi:10.1038/s41368-021-00131-7 · Cited by 313 · see citing works

Dysregulation of microRNAs in cancer: Playing with fire

Melo, S. A., & Esteller, M. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.08.009 · Cited by 317 · see citing works

Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression

Li, Y., Yang, J., Aguilar, A., McEachern, D., Przybranowski, S., Liu, L., Yang, C.-Y., Wang, M., Han, X., & Wang, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00909 · Cited by 312 · see citing works

Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges

Wang, S., Zhao, Y., Aguilar, A., Bernard, D., & Yang, C.-Y. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026245 · Cited by 300 · see citing works

MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models

Tovar, C., Graves, B., Packman, K., Filipovic, Z., Xia, B. H. M., Tardell, C., Garrido, R., Lee, E., Kolinsky, K., To, K.-H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2807 · Cited by 283 · see citing works

Hydrocarbon Stapled Peptides as Modulators of Biological Function

Cromm, P. M., Spiegel, J., & Grossmann, T. N. (2015) · ACS Chemical Biology · doi:10.1021/cb501020r · Cited by 289 · see citing works

Regulation of the p53 response and its relationship to cancer

Meek, D. W. (2015) · Biochemical Journal · doi:10.1042/bj20150517 · Cited by 291 · see citing works

Pathological Unfoldomics of Uncontrolled Chaos: Intrinsically Disordered Proteins and Human Diseases

Uversky, V. N., Davé, V., Iakoucheva, L. M., Malaney, P., Metallo, S. J., Pathak, R. R., & Joerger, A. C. (2014) · Chemical Reviews · doi:10.1021/cr400713r · Cited by 288 · see citing works

A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53

Bernal, F., Wade, M. R., Godes, M., Davis, T. N., Whitehead, D. G., Kung, A. L., Wahl, G. M., & Walensky, L. D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.024 · Cited by 284 · see citing works

The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway.

Korotchkina, L. G., Leontieva, O. V., Bukreeva, E. I., Demidenko, Z. N., Gudkov, A. V., & Blagosklonny, M. V. (2010) · Aging · doi:10.18632/aging.100160 · Cited by 278 · see citing works

Paradoxical suppression of cellular senescence by p53

Demidenko, Z. N., Korotchkina, L. G., Gudkov, A. V., & Blagosklonny, M. V. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002298107 · Cited by 273 · see citing works

The complexity of TRIM28 contribution to cancer

Czerwińska, P., Mazurek, S., & Wiznerowicz, M. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0374-4 · Cited by 272 · see citing works

A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis.

Kracikova, M., Akiri, G., George, A., Sachidanandam, R., & Aaronson, S. A. (2013) · Cell Death &amp; Differentiation · doi:10.1038/cdd.2012.155 · Cited by 261 · see citing works

Structure of the Stapled p53 Peptide Bound to Mdm2

Baek, S., Kutchukian, P. S., Verdine, G. L., Huber, R., Holak, T. A., Lee, K. W., & Popowicz, G. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja2090367 · Cited by 259 · see citing works

MicroRNA regulation of core apoptosis pathways in cancer

Lima, R. T., Busacca, S., Almeida, G. M., Gaudino, G., Fennell, D. A., & Vasconcelos, M. H. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.11.005 · Cited by 260 · see citing works

MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer

Tisato, V., Voltan, R., Gonelli, A., Secchiero, P., & Zauli, G. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0500-5 · Cited by 255 · see citing works

Oncogene-induced senescence: the bright and dark side of the response

Gorgoulis, V. G., & Halazonetis, T. D. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2010.07.013 · Cited by 257 · see citing works

Halogen-Enriched Fragment Libraries as Leads for Drug Rescue of Mutant p53

Wilcken, R., Liu, X., Zimmermann, M. O., Rutherford, T. J., Fersht, A. R., Joerger, A. C., & Boeckler, F. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja301056a · Cited by 243 · see citing works

Modulation of Protein–Protein Interactions for the Development of Novel Therapeutics

Πέττα, Ι., Lievens, S., Libert, C., Tavernier, J. H., & Bosscher, K. D. (2015) · Molecular Therapy · doi:10.1038/mt.2015.214 · Cited by 240 · see citing works

Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms

Allen, M. A., Andrysík, Z., Dengler, V. L., Mellert, H. S., Guarnieri, A. L., Freeman, J. A., Sullivan, K. D., Galbraith, M. D., Luo, X., Kraus, W. L., et al. (2014) · eLife · doi:10.7554/elife.02200 · Cited by 238 · see citing works

Small molecule induced reactivation of mutant p53 in cancer cells

Liu, X., Wilcken, R., Joerger, A. C., Chuckowree, I., Amin, J., Spencer, J., & Fersht, A. R. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt305 · Cited by 235 · see citing works

ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis

Shi, Y., Nikulenkov, F., Zawacka‐Pankau, J., Li, H., Gabdoulline, R. R., Xu, J., Eriksson, S. E., Hedström, E., Issaeva, N., Kel, A. E., et al. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2013.186 · Cited by 232 · see citing works

In Vivo Activation of the p53 Tumor Suppressor Pathway by an Engineered Cyclotide

Ji, Y., Majumder, S., Millard, M., Borra, R., Bi, T., Elnagar, A. Y., Neamati, N., Shekhtman, A. G., & Camarero, J. A. (2013) · Journal of the American Chemical Society · doi:10.1021/ja405108p · Cited by 233 · see citing works

Staying alive

Valcourt, J. R., Lemons, J. M. S., Haley, E. M., Kojima, M. L., Demuren, O. O., & Coller, H. A. (2012) · Cell Cycle · doi:10.4161/cc.19879 · Cited by 229 · see citing works

Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization

Graves, B., Thompson, T., Xia, M., Janson, C., Lukacs, C., Deo, D., Di Lello, P., Fry, D., Garvie, C., Huang, K.-S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203789109 · Cited by 230 · see citing works

D-peptide inhibitors of the p53–MDM2 interaction for targeted molecular therapy of malignant neoplasms

Liu, M., Li, C., Pazgier, M., Li, C., Mao, Y., Lv, Y., Gu, B., Wei, G., Yuan, W., Zhan, C., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008930107 · Cited by 229 · see citing works

Antitumoral activity of quinoxaline derivatives: A systematic review

Montana, M., Mathias, F., Terme, T., & Vanelle, P. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.059 · Cited by 228 · see citing works

Drugging Undruggable Molecular Cancer Targets

Lazo, J. S., & Sharlow, E. R. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103440 · Cited by 225 · see citing works

The Consequences of Chromosome Segregation Errors in Mitosis and Meiosis

Potapova, T., & Gorbsky, G. J. (2017) · Biology · doi:10.3390/biology6010012 · Cited by 218 · see citing works

Functionalised staple linkages for modulating the cellular activity of stapled peptides

Lau, Y. H., de Andrade, P., Quah, S. T., Rossmann, M., Laraia, L., Sköld, N., Sum, T. J., Rowling, P. J. E., Joseph, T. L., Verma, C. S., et al. (2014) · Chemical Science · doi:10.1039/c4sc00045e · Cited by 215 · see citing works

An insight into the therapeutic potential of quinazoline derivatives as anticancer agents

Shagufta, S., & Ahmad, I. (2017) · MedChemComm · doi:10.1039/c7md00097a · Cited by 213 · see citing works

Stapled Peptides with Improved Potency and Specificity That Activate p53

Brown, C. J., Quah, S. T., Jong, J., Goh, A. M., Chiam, P. C., Khoo, K. H., Choong, M. L., Lee, M. A., Yurlova, L., Zolghadr, K., et al. (2012) · ACS Chemical Biology · doi:10.1021/cb3005148 · Cited by 206 · see citing works

Prognostic impact and targeting of CRM1 in acute myeloid leukemia

Kojima, K., Kornblau, S. M., Ruvolo, V. R., Dilip, A., Duvvuri, S. R., Davis, R. E., Zhang, M., Wang, Z., Coombes, K. R., Zhang, N., et al. (2013) · Blood · doi:10.1182/blood-2012-08-447581 · Cited by 207 · see citing works

Stress-Responsive Sestrins Link p53 with Redox Regulation and Mammalian Target of Rapamycin Signaling

Budanov, A. V. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3530 · Cited by 203 · see citing works

Antimitotic drugs in the treatment of cancer

van Vuuren, R. J., Visagie, M. H., Mercier, A. E., & Joubert, A. M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2903-8 · Cited by 200 · see citing works

Protein-protein interaction networks: probing disease mechanisms using model systems

Kuzmanov, U., & Emili, A. (2013) · Genome Medicine · doi:10.1186/gm441 · Cited by 197 · see citing works

Targeting the ubiquitin–proteasome system for cancer therapy

Shen, M., Schmitt, S. M., Buac, D., & Dou, Q. P. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.815728 · Cited by 197 · see citing works

Endogenous Retroviruses and the Development of Cancer

Kassiotis, G. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302972 · Cited by 190 · see citing works

Dual Targeting of EGFR and HER3 with MEHD7945A Overcomes Acquired Resistance to EGFR Inhibitors and Radiation

Huang, S., Li, C., Armstrong, E. A., Peet, C. R., Saker, J., Amler, L. C., Sliwkowski, M. X., & Harari, P. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1611 · Cited by 190 · see citing works

Recent Advances in p53 Research and Cancer Treatment

Suzuki, K., & Matsubara, H. (2011) · BioMed Research International · doi:10.1155/2011/978312 · Cited by 187 · see citing works

The TP53 website: An integrative resource centre for the TP53 mutation database and TP53 mutant analysis

Leroy, B., Fournier, J. L., Ishioka, C., Monti, P., Inga, A., Fronza, G., & Soussi, T. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks1033 · Cited by 185 · see citing works

Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation

Topatana, W., Juengpanich, S., Li, S., Cao, J., Hu, J., Lee, J., Suliyanto, K., Ma, D., Zhang, B., Chen, M., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00956-5 · Cited by 182 · see citing works

Genetic and Epigenetic Signatures in Human Hepatocellular Carcinoma:A Systematic Review

Nishida, N., & Goel, A. (2011) · Current Genomics · doi:10.2174/138920211795564359 · Cited by 180 · see citing works

Local activation of p53 in the tumor microenvironment overcomes immune suppression and enhances antitumor immunity

Guo, G., Yu, M., Xiao, W., Celis, E., & Cui, Y. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2832 · Cited by 168 · see citing works

Aneuploidy and chromosomal instability: a vicious cycle driving cellular evolution and cancer genome chaos

Potapova, T., Zhu, J., & Li, R. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9436-6 · Cited by 168 · see citing works

p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewalPreprint

Zhao, Z., Zuber, J. A., Díaz-Flores, E., Lintault, L., Kogan, S. C., Shannon, K., & Lowe, S. W. (2010) · Genes & Development · doi:10.1101/gad.1940710 · Cited by 167 · see citing works

The Structure‐Based Design of Mdm2/Mdmx–p53 Inhibitors Gets Serious

Popowicz, G. M., Dömling, A. S. S., & Holak, T. A. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201003863 · Cited by 166 · see citing works

The role of DNA damage responses in p53 biology

Speidel, D. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1459-z · Cited by 165 · see citing works

Reactive Oxygen Species Induced p53 Activation: DNA Damage, Redox Signaling, or Both?

Shi, T., & Dansen, T. B. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8074 · Cited by 164 · see citing works

Mage-A Cancer/Testis Antigens Inhibit p53 Function by Blocking Its Interaction with Chromatin

Marcar, L., MacLaine, N. J., Hupp, T. R., & Meek, D. W. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1341 · Cited by 158 · see citing works

Current strategies to target p53 in cancer

Chen, F., Wang, W., & El‐Deiry, W. S. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.04.031 · Cited by 158 · see citing works

Small Molecule Structure Correctors Abolish Detrimental Effects of Apolipoprotein E4 in Cultured Neurons

Chen, H.-K., Liu, Z., Meyer-Franke, A., Brodbeck, J., Miranda, R. D., McGuire, J. G., Pleiss, M. A., Ji, Z.-S., Balestra, M. E., Walker, D. W., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.276162 · Cited by 163 · see citing works

Silver-Based Nanoparticles Induce Apoptosis in Human Colon Cancer Cells Mediated Through P53

Satapathy, S. R., Mohapatra, P., Preet, R., Das, D., Sarkar, B., Choudhuri, T., Wyatt, M. D., & Kundu, C. N. (2013) · Nanomedicine · doi:10.2217/nnm.12.176 · Cited by 150 · see citing works

Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers

Ehsanian, R., Waes, C. V., & Feller, S. M. (2011) · Cell Communication and Signaling · doi:10.1186/1478-811x-9-13 · Cited by 147 · see citing works

Protein Regulation in Signal TransductionPreprint

Lee, M. J., & Yaffe, M. B. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a005918 · Cited by 148 · see citing works

Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists

Shen, H., & Maki, C. G. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222603 · Cited by 143 · see citing works

Systematic Mutational Analysis of Peptide Inhibition of the p53–MDM2/MDMX Interactions

Li, C. V., Pazgier, M., Li, C., Yuan, W., Liu, M., Wei, G., Lu, W., & Lu, W. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.03.005 · Cited by 146 · see citing works

Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine

Fiorini, C., Cordani, M., Padroni, C., Blandino, G., Agostino, S. D., & Donadelli, M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.10.003 · Cited by 144 · see citing works

The DNA damage response and immune signaling alliance: Is it good or bad? Nature decides when and where

Pateras, I. S., Havaki, S., Nikitopoulou, X., Vougas, K. N., Townsend, P. A., Panayiotidis, M. I., Georgakilas, A. G., & Gorgoulis, V. G. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.06.011 · Cited by 143 · see citing works

Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells

Puca, R., Nardinocchi, L., Givol, D., & D’Orazi, G. (2010) · Oncogene · doi:10.1038/onc.2010.183 · Cited by 140 · see citing works

Pharmacological reactivation of mutant p53: from protein structure to the cancer patient

Wiman, K. G. (2010) · Oncogene · doi:10.1038/onc.2010.188 · Cited by 140 · see citing works

p53 Isoforms and Their Implications in Cancer

Vieler, M., & Sanyal, S. (2018) · Cancers · doi:10.3390/cancers10090288 · Cited by 140 · see citing works

Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture

Apontes, P., Leontieva, O. V., Demidenko, Z. N., Li, F., & Blagosklonny, M. V. (2011) · Oncotarget · doi:10.18632/oncotarget.248 · Cited by 138 · see citing works

“Recycling” Classical Drugs for Malaria

Teixeira, C. A. S., Vale, N., Pérez, B. C., Gomes, A., Gomes, J. R. B., & Gomes, P. A. C. (2014) · Chemical Reviews · doi:10.1021/cr500123g · Cited by 136 · see citing works

Cellular senescence and cancer chemotherapy resistance

Gordon, R. R., & Nelson, P. S. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.002 · Cited by 134 · see citing works

Wild-type p53 controls cell motility and invasion by dual regulation of MET expression

Hwang, C., Matoso, A., Corney, D. C., Flesken‐Nikitin, A., Körner, S., Wang, W., Boccaccio, C., Thorgeirsson, S. S., Comoglio, P. M., Hermeking, H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017536108 · Cited by 133 · see citing works

Nucleotide Biosynthetic Enzyme GMP Synthase Is a TRIM21-Controlled Relay of p53 Stabilization

Reddy, B. A., van der Knaap, J. A., Bot, A. G. M., Mohd-Sarip, A., Dekkers, D. H. W., Timmermans, M. A. M., Martens, J. W. M., Demmers, J., & Verrijzer, C. P. (2014) · Molecular Cell · doi:10.1016/j.molcel.2013.12.017 · Cited by 131 · see citing works

Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer

Galluzzi, L., Vitale, I., Senovilla, L., Olaussen, K. A., Pinna, G., Eisenberg, T., Goubar, A., Martins, I., Michels, J., Kratassiouk, G., et al. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.06.017 · Cited by 133 · see citing works

Voxelwise gene-wide association study (vGeneWAS): Multivariate gene-based association testing in 731 elderly subjects

Hibar, D. P., Stein, J. L., Omid Kohannim, A., Jahanshad, N., Saykin, A. J., Shen, L., Kim, S., Pankratz, N., Foroud, T., Huentelman, M. J., et al. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.03.077 · Cited by 128 · see citing works

Schiff Bases and their Metal Complexes as Potential Anticancer Candidates: A Review of Recent Works

Tadele, K. T., & Tsega, T. W. (2019) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520619666190227171716 · Cited by 130 · see citing works

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial

Bonnefoi, H. R., Piccart, M. J., Bogaerts, J., Mauriac, L., Fumoleau, P., Brain, E. G. C., Petit, T., Rouanet, P., Jassem, J., Blot, E., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70094-8 · Cited by 128 · see citing works

Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications

Perri, F., Pacelli, R., Scarpati, G. D. V., Cella, L., Giuliano, M., Caponigro, F., & Pepe, S. (2014) · Head & Neck · doi:10.1002/hed.23837 · Cited by 128 · see citing works

Double Strain‐Promoted Macrocyclization for the Rapid Selection of Cell‐Active Stapled Peptides

Lau, Y. H., Wu, Y., Rossmann, M., Tan, B. X., de Andrade, P., Tan, Y. S., Verma, C. S., McKenzie, G. J., Venkitaraman, A. R., Hyvönen, M., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201508416 · Cited by 126 · see citing works

Understanding and Managing Ultra High-Risk Chronic Lymphocytic Leukemia

Stilgenbauer, S., & Zenz, T. (2010) · Hematology · doi:10.1182/asheducation-2010.1.481 · Cited by 125 · see citing works

Small-Molecule Structure Correctors Target Abnormal Protein Structure and Function: Structure Corrector Rescue of Apolipoprotein E4–Associated Neuropathology: Miniperspective

Mahley, R. W., & Huang, Y. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3008618 · Cited by 132 · see citing works

Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition

Wilcken, R., Wang, G., Boeckler, F. M., & Fersht, A. R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211550109 · Cited by 120 · see citing works

The nucleolus as a fundamental regulator of the p53 response and a new target for cancer therapy

Woods, S. J., Hannan, K. M., Pearson, R. B., & Hannan, R. D. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.10.007 · Cited by 116 · see citing works

Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and <i>MDM2</i> Amplification in Sarcomagenesis

Ito, M., Barys, L., O'Reilly, T., Young, S., Gorbatcheva, B., Monahan, J., Zumstein-Mecker, S., Choong, P. F., Dickinson, I., Crowe, P., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2050 · Cited by 115 · see citing works

Drugging the p53 pathway: understanding the route to clinical efficacy

Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 723 · see citing works

Small molecule compounds targeting the p53 pathway: are we finally making progress?

Yu, X., Narayanan, S., Vázquez, A., & Carpizo, D. R. (2014) · APOPTOSIS · doi:10.1007/s10495-014-0990-3 · Cited by 65 · see citing works

ORIGINAL PAPER Small molecule compounds targeting the p53 pathway: are we finally making progress?

Yu, X., Narayanan, S., Vazquez, A., & Carpizo, D. R. (2014)

The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches

Joerger, A. C., & Fersht, A. R. (2016) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014710 · Cited by 658 · see citing works

Translational approaches targeting the p53 pathway for anti‐cancer therapy

Essmann, F., & Schulze‐Osthoff, K. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01570.x · Cited by 77 · see citing works